Prostate cancer (PCa) remains the most frequently occurring non-cutaneous solid malignancy in men from Western countries and represents the second leading cause of cancer-related death next to lung cancer[@b1][@b2]. The incidence of PCa in China, although lower than in developed countries, has increased remarkably partly due to the increasing life expectancy, dietary changes and Westernized lifestyle[@b3]. Recently, accumulated evidence suggests that genetic factors, such as genetic polymorphisms, may contribute to the etiology of PCa[@b4][@b5][@b6].

Aberrant DNA methylation plays an essential role in prostatic tumorigenesis by stimulating proto-oncogenes and inactivating tumor suppressor genes[@b7][@b8]. Alteration of DNA methylation is often identified in PCa and is associated with PCa initiation by regulating gene expression and promoting chromosomal instability[@b9][@b10][@b11]. Several epigenetic mechanisms related to one-carbon metabolism involving DNA and histone methylation, DNA uracil misincorporation, and chromosomal rearrangements have been observed in PCa cells[@b12][@b13]. The one-carbon metabolism pathway is a complex network of interdependent reactions that facilitates the transfer of one-carbon units and ultimately provides various forms of precursors needed for DNA synthesis, repair and methylation. Numerous studies showed that one-carbon metabolism gene polymorphisms were associated with the balance of one-carbon metabolism and the genome-wide DNA methylation levels in breast cancer and colorectal cancer[@b14][@b15][@b16][@b17]. Moreover, our previous study identified several noncoding variants within one-carbon metabolism genes were able to impair the one-carbon metabolism balance and were associated with increased risk of birth defect[@b18][@b19][@b20]. However, whether those noncoding variants contributed to the occurrence of cancer remains unknown. Thus, investigating the roles of one-carbon metabolism gene variations in the cancer development is a topic of much current interest. Studies addressing the relationship between polymorphisms of one-carbon metabolism genes and the risk of various cancers, including colorectal cancer, breast cancer and malignant lymphoma, have yielded conflicting results[@b21][@b22][@b23][@b24][@b25]. Few studies have addressed the effects of one-carbon metabolism gene polymorphisms on the risk of PCa, and the results have been inconsistent[@b4][@b5][@b6]. Marchal and colleagues explored the association between polymorphisms of *MTHFR* (rs1801133, rs1801131), *MTR* (rs1805087) and *MTRR* (rs1801394) genes and risk of PCa in a Spain cohort and found *MTHFR* rs1801131 is clearly related to prostatic carcinogenesis[@b6]. Collin *et al.*[@b4] investigated the effect of eight single nucleotide polymorphisms (SNPs), including *MTHFR* rs1801133, *MTHFR* rs1801131, *MTR* rs1805087, *MTRR* rs1801394, *MTHFD1* rs2236225, *SLC19A1/RFC1* rs1051266, *SHMT1* rs1979277 and *FOLH1* rs202676, on PCa risk in a meta-analysis and found no significant effects of any SNPs on susceptibility to PCa.

The accumulation of homocysteine causes elevated levels of its precursor S-adenosylhomocysteine (SAH), thus leading to aberrant DNA methyltransferase activity[@b26][@b27][@b28][@b29][@b30]. For this reason, the role of homocysteine removal gene polymorphisms in modulating the risk of PCa warrants further research. Furthermore, to the best of our knowledge, there are few studies of the possible correlation between genetic variations in the noncoding region of one-carbon metabolism genes and PCa risk have been published. The aim of the present study was to investigate the contribution of functional non-coding variants to the risk of PCa in a large-scale hospital-based case-control study, including *MTR* rs28372871, *MTR* rs1131450, *MTRR* rs326119 and *CBS* rs2850144[@b18][@b19][@b20]. Moreover, we assessed the effects of other extensively reported polymorphisms of genes in the one-carbon metabolism pathway, including *MTR* rs1805087 and *MTRR* rs1801394[@b4][@b6][@b31], on the risk of PCa in our cohort.

Results
=======

Characteristics of the study subjects
-------------------------------------

The demographic characteristics of the entire cohort are displayed in [Table 1](#t1){ref-type="table"}. The cases and controls were matched well by age, with a mean age of 66.7 and 66.9, respectively (*P* = 0.437). There were no significant differences in the distribution of age, BMI, hypertension, diabetes mellitus or cardiovascular disease between 1817 cases and 2026 controls. Among the case subjects, 605 (33.3%) patients were Gleason score ≥8, 586 (32.3%) patients had extracapsular extension, 352 (19.4%) patients had positive surgical margins and 154 (8.5%) patients had lymph node involvement.

Association between one-carbon metabolism gene variants and PCa risk
--------------------------------------------------------------------

The genotype frequencies and their associations with the risk of PCa are summarized in [Table 2](#t2){ref-type="table"}. The genotype frequencies among the controls were all in agreement with Hardy-Weinberg equilibrium (HWE) (all *P* \> 0.05). The variants rs28372871, rs1131450 and rs1805087 within *MTR,* and rs326119 and rs1801394 within *MTRR*, were not in high linkage disequilibrium ([Supplementary Tables 1](#S1){ref-type="supplementary-material"} and [2](#S1){ref-type="supplementary-material"}). Significant differences in genotype distributions between cases and controls were observed for the non-coding *MTR* variants rs28372871 T \> G (*P* = 3 × 10^−4^) and rs1131450 G \> A (*P* = 2 × 10^−4^). The homozygous GG genotype of rs28372871 in the *MTR* gene promoter (crude OR = 1.44, 95% CI: 1.20--1.73, *P* = 3 × 10^−4^) and the homozygous AA genotype of rs1131450 in the 3′UTR of the *MTR* gene (crude OR = 1.77, 95% CI: 1.30--2.41, *P* = 2 × 10^−4^) were associated with a significantly increased risk of PCa compared with their respective homozygous wild-type genotypes. Furthermore, both the above-mentioned genotypes maintained their statistical significance in multivariate logistic regression analyses after adjusting for age, BMI, hypertension, diabetes mellitus and cardiovascular disease. Compared with the homozygous wild-types, there was a 1.40-fold increased risk of PCa associated with the *MTR* rs28372871 GG genotype (adjusted OR = 1.40, 95% CI: 1.15--1.71, *P* = 0.004) and a 1.64-fold increased risk associated with the *MTR* rs1131450 AA genotype (adjusted OR = 1.64, 95% CI: 1.17--2.31, *P* = 0.007). Nevertheless, we did not observe statistical evidence to support associations of the other SNPs with PCa risk ([Table 2](#t2){ref-type="table"}).

Stratification analysis
-----------------------

Further stratified analyses were performed to investigate associations between the SNPs evaluated and PCa risk by recessive, dominant and log-additive genetic model, respectively ([Table 3](#t3){ref-type="table"}, [Supplementary Tables 3](#S1){ref-type="supplementary-material"} and [4](#S1){ref-type="supplementary-material"}). The multivariate logistic regression analyses revealed that the *MTR* rs28372871 GG genotype and rs1131450 AA genotype were associated with an increased risk of PCa, particularly in subgroups of Gleason score ≥8, positive extracapsular extension, positive seminal vesicle invasion and positive lymph node involvement in all three models, as supported by homogeneity tests (all *P* \< 0.05). In addition, although increased risk was observed among subgroups of BMI ≥ 25 kg/m^2^ and lacking diabetes mellitus for patients carrying *MTR* rs28372871 GG genotype and among subgroups of age ≤68 years and without cardiovascular disease for those carrying *MTR* rs1131450 AA genotype in all three models, further homogeneity tests did not support any difference in the estimates of PCa risk between these strata.

The promoter rs28372871 decreases *MTR* transcriptional activity in PCa cell lines and prostate tissues
-------------------------------------------------------------------------------------------------------

Because the rs28372871 T \> G variant is located in the core promoter region of the *MTR* gene, we speculated that it might influence *MTR* transcription. Thus, we carried out *in vitro* luciferase reporter assays in the PCa cell lines LNCaP and PC3 and compared mRNA levels among different genotypes of the rs28372871 T \> G variant in 52 human prostate tissue samples to assess the functional consequence of variant rs28372871 T \> G on *MTR* transcriptional activity. The luciferase assay revealed that a plasmid containing the minor G allele provided significantly lower luciferase expression in comparison with the major A allele with a 47.2% reduction in LNCaP cells and a 51.4% reduction in PC3 cells ([Fig. 1A](#f1){ref-type="fig"}). Data from human prostate tissue showed that samples with the rs28372871 TG and GG genotypes displayed 27.7% and 48.5% reductions in *MTR* gene expression, respectively, compared with the TT genotype ([Fig. 1B](#f1){ref-type="fig"}). These consistent findings confirmed our hypothesis that the promoter rs28372871 T \> G variant functionally reduces the transcription of *MTR*.

The variant rs1131450 G \> A reduces *MTR* expression
-----------------------------------------------------

To investigate whether the rs1131450 G \> A variant affects *MTR* expression, we performed *in vitro* luciferase reporter assays and assess the functional consequence of variant rs1131450 G \> A on *MTR* transcriptional activity. The results of the transfection experiments showed that the plasmid construct carrying the mutant A allele manifested a 31.1% reduction in luciferase activity compared with that carrying the wild type G allele in LNCaP cells. There was a 26.0% reduction in PC3 cells ([Fig. 1C](#f1){ref-type="fig"}). However, real-time PCR results showed that the variant rs1131450 was not related to *MTR* gene expression in human prostate tissue samples ([Fig. 1D](#f1){ref-type="fig"}). Since the luciferase results indicated the protein level of target vector, these findings indicate that subjects carrying the *MTR* rs1131450 A allele might be at higher risk for PCa due to a reduction in MTR protein expression.

*MTR* variants correlate with human plasma homocysteine concentration
---------------------------------------------------------------------

MTR is responsible for the remethylation of homocysteine to methionine, which is essential for maintaining normal homocysteine concentrations. Because the rs28372871 and rs1131450 variants could reduce *MTR* expression and be correlated with plasma homocysteine concentration in adolescence, we assumed that those variants also determine homocysteine levels in the PCa susceptible population. To test this hypothesis, we explored the relationship between the two variants and plasma homocysteine levels in 201 PCa patients and 210 matched control subjects. Our results regarding the rs28372871 T \> G variant showed that the TG and GG genotypes were significantly associated with elevated plasma homocysteine levels compared with the wild-type TT genotype in PCa and control subgroups as well as in combined analysis (all *P* \< 0.05) ([Fig. 2A](#f2){ref-type="fig"}). With regard to the rs1131450 G \> A variant, carriers of the homozygous mutant AA genotype had the highest plasma homocysteine concentration, which was approximately 1.5-fold higher than those carrying the homozygous GG genotype in the PCa cohort, the control cohort and the entire cohort ([Fig. 2B](#f2){ref-type="fig"}).

Down-regulation of *MTR* elevates cellular homocysteine and SAH levels and reduces methionine and SAM levels in PCa cell lines
------------------------------------------------------------------------------------------------------------------------------

Furthermore, we detected cellular homocysteine, methionine, SAM and SAH concentrations in PC3 and LNCaP cells after gradient transfection with *MTR* siRNA. The *MTR* knockdown efficiency and metabolites quantification in PC3 cells were shown in [Fig. 3](#f3){ref-type="fig"}. The results of quantitative real-time PCR, which was performed to determine the knockdown efficiency, showed that the expression of *MTR* was down-regulated in a dose-dependent manner ([Fig. 3A](#f3){ref-type="fig"}). We observed elevated cellular homocysteine levels and reduced methionine levels with decreasing *MTR* expression ([Fig. 3B,C](#f3){ref-type="fig"}). Moreover, decreased SAM concentration, increased SAH concentration, and an increased SAH/SAM ratio were observed when *MTR* expression decreased ([Fig. 3D--F](#f3){ref-type="fig"}). Results obtained in LNCaP cells were consistent with those in PC3 cells ([Supplementary Figure 2](#S1){ref-type="supplementary-material"}). These findings suggested that reduced *MTR* expression led to increased homocysteine levels and reduced cellular methylation potential.

Down-regulation of *MTR* promotes cell invasion *in vitro*
----------------------------------------------------------

Taking into consideration that the *MTR* genotype of risk led to nearly 50% reduction in *MTR* expression *in vivo* ([Fig. 1B](#f1){ref-type="fig"}), LNCaP and PC3 cells with approximately 50% reduced *MTR* expression were constructed using siRNA ([Fig. 4A](#f4){ref-type="fig"}). CCK-8 assays indicated that the approximately 50% reduction of *MTR* did not alter LNCaP or PC3 cell proliferation ([Fig. 4B,C](#f4){ref-type="fig"}). However, in the PC3 cell invasion assay, we found that *MTR* knockdown significantly increased the number of invading cells following 24 hours of incubation compared with non-transfected cells ([Fig. 4D](#f4){ref-type="fig"} and [Supplementary Figure 1](#S1){ref-type="supplementary-material"}).

Discussion
==========

In the current large-scale hospital-based case-control study, we conducted a comprehensive analysis of a panel of genetic polymorphisms in 3 homocysteine removal genes involved in one-carbon metabolism and risk of PCa in 1817 cases and 2026 controls from an ethnic Han Chinese population. We found that two genetic variants in the regulatory regions of the *MTR* gene, rs28372871 T \> G and rs1131450 G \> A, were associated with a significantly increased risk of PCa. In previous study we proved that rs28372871 destroyed the transcription factor binding site in *MTR* promoter and rs1131450 enhanced the binding affinity of miRNA to the *MTR* 3′UTR[@b18]. In the current study, further functional analyses revealed that these two variants reduced the expression of the *MTR* gene *in vitro* and *in vivo*, elevated homocysteine and SAH levels, reduced methionine and SAM levels, increased the SAH/SAM ratio, and promoted the invasion of PCa cells *in vitro*. To the best of our knowledge, this is the first study to investigate the association between genetic variations in the noncoding region of one-carbon metabolism genes and risk of PCa.

MTR, one of the key enzymes in one-carbon metabolism, is responsible for the remethylation of homocysteine to methionine, thereby removing homocysteine. Consecutively, methionine is metabolized to yield SAM, which is the main methyl donor for methylation reactions. Studies addressing the relationship between *MTR* gene polymorphisms and risk of various cancers have yielded contradictory results. It was reported that *MTR* polymorphisms increase the risk of colorectal cancer[@b21], breast cancer[@b22], and malignant lymphoma[@b23], but these findings have not been confirmed in other studies[@b24][@b25]. In a meta-analysis of one-carbon metabolism genes and risk of PCa, Collin *et al.* found that the *MTR* c.2756 A \> G polymorphism was positively associated with PCa risk[@b4]. However, another study reported that there was no risk or statistically significant association between *MTR* polymorphism and PCa[@b5]. In the present study, we found that two noncoding *MTR* variants, rs28372871 T \> G and rs1131450 905G \> A, were independently associated with a significantly increased risk of PCa. The homozygous GG genotype of the variant rs28372871 in the promoter region (adjusted OR = 1.40, *P* = 0.004) and the homozygous AA genotype of the variant rs1131450 in the 3′UTR region (adjusted OR = 1.64, *P* = 0.007) exhibited a 1.40-fold and a 1.64-fold higher risk of PCa, respectively, compared with their respective homozygous wild-type genotypes in multivariate analyses. Furthermore, functional experiments revealed that both of the risk *MTR* allelic variants reduce *MTR* expression significantly. Decreased MTR expression results in elevated homocysteine levels with a simultaneous reduction of methionine production, consequently leading to an increased SAH/SAM ratio, which represents decreased methylation ability. Therefore, we inferred that the functional *MTR* variants rs28372871 and rs1131450 increase the risk of PCa via impairing methylation reactions considering that global DNA hypomethylation is a feature of prostatic tumorigenesis[@b32][@b33][@b34].

MTRR catalyzes the regeneration of methylcobalamin, a cofactor of MTR, keeping MTR active. This is the first study to examine the association of the *MTRR* rs326119 polymorphism with the risk of PCa, and we report null results. Moreover, we did not observe an association between rs1801394, the most frequently studied *MTRR* polymorphism, and the risk of PCa. Previous studies that examined the *MTRR* rs1801394 polymorphism in relation to PCa risk generally showed null results, which is consistent with our results[@b4][@b6].

CBS, as a rate-limiting enzyme, catalyzes the first irreversible step from homocysteine to cystathionine in the transsulfuration pathway. So far, few studies concerning the association between genetic polymorphisms in *CBS* and PCa risk have been published[@b5]. Kimura *et al.*[@b5] investigated the association of *CBS* 844ins68 polymorphism and susceptibility to PCa and found no significant association. In this study, we found that the polymorphism rs2850144 C \> G in the *CBS* gene promoter region was not associated with PCa risk. Recently, Zhang *et al.* observed an association between the *CBS* rs706209 polymorphism and clear cell renal cell carcinoma risk in the Chinese population[@b35]. Soon afterwards, Gallegos-Arreola and colleagues reported that the 844ins68 polymorphism in the *CBS* gene contributes significantly to breast cancer susceptibility in Mexican population[@b36]. Nevertheless, negative results have been observed with regard to different types of cancer[@b37][@b38][@b39]. Various factors, including differences in study design, study population and dietary assessment, could contribute to these inconsistent findings.

We acknowledge that there are certain limitations in the present study. Firstly, this hospital-based case-control study may have some selection and information biases, although these might be minimized by the age-matching between cases and controls as well as the adjustment for potential confounding factors in the statistical analyses. Secondly, although we investigated six SNPs in three key genes thought to be important in PCa risk in the one-carbon metabolism pathway, other potentially functional genetic variants may not have been included in the current study. Another potential limitation of this study is that the modest number of cases in the stratified analyses may limit the statistical power to examine the genetic variants with regard to the risk of PCa. Finally, the lack of data on folate intake and levels prohibits the evaluation of their effects on genetic variants in one-carbon metabolism genes and risk of PCa, thus limiting our conclusions. Notwithstanding these limitations, the results of the current study underscore that genetic variants in one-carbon metabolism genes may influence their function in one-carbon supply and subsequently result in elevated homocysteine levels and aberrant DNA methylation, thereby modifying PCa risk.

In summary, this large-scale hospital-based case-control study revealed that two functional variants in the regulatory regions of the *MTR* gene, rs28372871 T \> G and rs1131450 G \> A, were associated with a significantly increased risk of PCa by reducing *MTR* expression, elevating homocysteine and SAH levels, reducing methionine and SAM levels, increasing the SAH/SAM ratio, and promoting invasion by PCa cells. Our findings suggest that one-carbon metabolism plays a vital role in the etiology of PCa, and further investigation of gene-gene and gene-environment interactions in one-carbon metabolism is warranted.

Materials and Methods
=====================

Study population
----------------

This hospital-based case-control study recruited 1817 eligible patients with newly diagnosed PCa and 2026 matched cancer-free controls from genetically unrelated ethnic Han Chinese participants treated at Fudan University Shanghai Cancer Center from January 2008 to June 2015. All cases had histologically confirmed primary prostate adenocarcinoma assessed independently by two pathologists in routine diagnosis. All pathologic diagnoses were performed according to the WHO criteria for PCa. Cases who had malignancies other than primary PCa, had a family history of PCa and those who had radiotherapy or chemotherapy before enrollment were excluded. The tumor stage was determined and categorized according to the American Joint Committee on Cancer (AJCC) TNM classification system[@b40]. Histopathological grading was performed according to the Gleason score system. Patient clinicopathological characteristics including age, height, weight, serum PSA level at diagnosis, characteristics at surgery (tumor grade, tumor stage, surgical margin status and lymph node involvement) and comorbidities (hypertension, diabetes mellitus and cardiovascular disease) were extracted from the archival medical records.

The 2026 male cancer-free control subjects were frequency-matched to cases by age and geographic area and were recruited during the same period. Due to population-based PCa screening using PSA and digital rectal examination not being a routine practice in China, those who suffered from low urinary tract symptoms were advised to have serum PSA testing and a digital rectal examination, and subjects with serum PSA \> 4 ng/mL with or without an abnormal digital rectal examination were excluded from the control group. The study was carried out in accordance with the ethical standards of the Helsinki Declaration II and approved by the Institution Review Board of Fudan University Shanghai Cancer Center. Written informed consent was obtained from each participant before any study-specific investigation was performed.

SNP identification and genotyping
---------------------------------

Genomic DNA was extracted from peripheral leukocytes by standard procedures using the Qiagen Blood DNA KIT (Qiagen Inc., Valencia, CA, USA). Polymorphisms in noncoding regions of the *MT*R (rs28372871, rs1131450), *MTRR* (rs326119) and *CBS* (rs2850144) genes were amplified by PCR. Selected SNPs, including polymorphisms in noncoding regions of the *MTR*, *MTRR* and *CBS* genes and the *MTR* rs1805087 and *MTRR* rs1801394 polymorphisms, were genotyped using SNaPshot analysis (ABI)[@b18][@b19][@b20]. Five percent of the genotyping results were validated using direct dye terminator sequencing of PCR products in accordance with the manufacturer's protocol of the ABI Prism BigDye system (ABI, Foster City, CA, USA). The samples for sequencing and genotyping were run on an ABI 3730 automated sequencer and analyzed by SeqMan and Peakscan, respectively.

Cell lines and cell culture
---------------------------

Human LNCaP and PC3 cell lines (The Cell Bank of Chinese Academy of Sciences, Shanghai) were cultured in RPMI 1640 media (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen). The cells were maintained in 5% CO~2~ at 37 °C and media was replaced every other day. Short tandem repeats genotyping and intermittent testing for androgen responsiveness (growth and androgen receptor activity) were performed to authenticate the cell lines. The genotypes of detected SNPs in these cell lines were detected and listed in [Supplementary Table 5](#S1){ref-type="supplementary-material"}.

Plasmid construction and luciferase reporter assay
--------------------------------------------------

The luciferase reporter plasmids were constructed as described before[@b18]. Briefly, 1304 bp *MTR* fragments from −1267 to +37 containing either T allele or G allele of rs28372871 were amplified by PCR from genomic DNA. After digestion with MluI and BglII, the PCR products were subcloned into the pGL3-Basic vector (Promega, Madison, WI, USA), in which the firefly luciferase gene was used as a reporter. To construct the *MTR* 3′UTR reporter plasmid, 878 bp fragments of the 3′UTR of the *MTR* gene containing either the G allele or A allele of rs1131450 were amplified from genomic DNA. The PCR products were subsequently digested using XhoI and BamHI and cloned into the 3′UTR of the *Renilla* luciferase gene of the psiCHECK-2 vector (Promega). The *Renilla* luciferase gene was used as a reporter, and its expression could be normalized to the firefly luciferase signal. The primers used are listed in [Supplementary Table 6](#S1){ref-type="supplementary-material"}.

In luciferase reporter assay, 1 μg of each *MTR* reporter plasmid and 20 ng of the pRL-TK plasmid (Promega) as an internal control were transfected into LNCaP or PC3 cells. After 24 hours of transfection, cell lysates were collected and subjected to luciferase assay using Dual-Luciferase Reporter Assay System (Promega). Each luciferase assay was performed in triplicate, and three independent transfection experiments were carried out.

Quantitative real-time PCR
--------------------------

We randomly collected 52 human prostate tissue samples from surgery of PCa patients and extracted total RNA using TransZol Up Plus Kit (Transgen Biotech, Beijing, China). After the total RNA was converted to cDNA using random hexamers, oligo primers and reverse transcriptase (Takara), the *MTR* mRNA were quantified by real-time PCR using the ABI Prism 7900 sequence detection system with *GAPDH* as an internal control. Each reaction was performed in triplicate. The primers utilized are listed in [supplementary Table 6](#S1){ref-type="supplementary-material"}.

siRNA transfection
------------------

*MTR* siRNA and mock siRNA negative control were chemically synthesized (Genepharma, Shanghai, China). For transfection, PC3 cells were seeded in six-well plates at 50--70% confluency. *MTR* siRNA was transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. At 48 hours after transfection, the cells were seeded for cell proliferation assays and invasion assays.

Plasma and cellular one-carbon metabolite quantification
--------------------------------------------------------

EDTA-plasma samples were randomly collected from 201 PCa patients and 210 cancer-free control participants, centrifuged immediately and frozen at −80 °C for quantifying the homocysteine levels. Plasma homocysteine levels were determined using the Axis® Homocysteine Enzyme Immunoassay (EIA) Kit (Axis-Shield, Norton, MA) according to the manufacturer's instructions.

PC3 cells were transfected with 0 pmol, 50 pmol, 100 pmol, 200 pmol, 400 pmol or 800 pmol of *MTR* siRNA. After 48 hours of transfection, the cells were harvested for the detection of metabolite levels. Cellular homocysteine levels were determined using the Axis® Homocysteine Enzyme Immunoassay (EIA) Kit. The levels of S-adenosylmethionine (SAM) and SAH were detected with a SAM & SAH ELISA Combo Kit (Cell Biolabs, San Diego, CA). The concentration of methionine was quantified by high-performance liquid chromatography (HPLC) as previously reported[@b41]. Each test was repeated in triplicate, and the mean level was used for further analysis.

Cell proliferation assay
------------------------

Cell proliferation after transfection was measured using the Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories, Kumamoto, Japan). Briefly, LNCaP and PC3 cells were seeded in 96-well plates. After incubation for 48 hours, CCK-8 solution (10 μl) was added to each well and incubated in a humidified CO~2~ incubator at 37 °C for 2 hours. Then, the absorbance of samples taken from each well was measured at 450 nm, on the basis of which the percentage of surviving cells in each treatment group was plotted relative to the untreated one.

Cell invasion assay
-------------------

Cellular invasion was measured using a Transwell chamber (Becton Dickinson, Franklin Lakes, NJ, USA) according to the manufacturer's protocol. Briefly, after transfection, 1 × 10^5^ PC3 cells suspended in 100 μl F-12K medium without fetal bovine serum were seeded in the upper chamber of Transwell inserts with a pore size of 8 μm. A volume of 600 μl F-12K medium containing 10% fetal bovine serum as a chemoattractant was added to the lower chamber. Subsequent to a 24 hour incubation, the Transwell insert was washed with PBS, and cells on the upper surface of the insert were gently removed with a cotton swab. Invading cells (lower surface of the insert) were fixed with 4% paraformaldehyde (Sigma-Aldrich) for 15 min and were stained with DAPI. All assays were independently repeated in triplicate. Five random microscopic fields were evaluated for each insert.

Statistical analysis
--------------------

Body mass index (BMI, kg/m^2^) was calculated as weight in kilograms divided by height in meters squared and was categorized according to the WHO cut point for obese (BMI ≥ 25 kg/m^2^) in Asian populations[@b42]. Hardy-Weinberg equilibrium (HWE) for evaluation of genotype distribution in the control subjects was calculated using the goodness-of fit χ^2^ test, and *P* \< 0.05 was considered deviated from the equilibrium. Univariate and multivariate unconditional logistic regression models were used to calculate crude and adjusted odds ratios (ORs) and 95% confidence intervals (CIs), respectively, to evaluate associations between the genotypes and PCa risk, with adjustments for age, BMI, hypertension, diabetes mellitus and cardiovascular disease in multivariate models. In addition, stratified analysis was performed to explore the association between the genotypes and risk of PCa among subgroups of age (≤68 vs. \>68), BMI (\<25 vs. ≥25), hypertension, diabetes mellitus, cardiovascular disease, Gleason score, extracapsular extension, seminal vesicle invasion, positive surgical margin and lymph node involvement. In the stratified analysis by age, patients were grouped using the median age (68 years old) as cutoff. The Chi-square-based Q test was performed to detect the homogeneity of associations between subgroups. For all statistical tests, a two-sided *P* \< 0.05 was considered statistically significant. All statistical analyses were performed using SPSS (Statistical Package for the Social Sciences) software version 16.0 (SPSS Inc., Chicago, IL, USA).
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![The *MTR* variants rs28372871 T \> G and rs1131450 G \> A down-regulate MTR expression at the levels of transcription and translation, respectively.\
(**A**) Luciferase expression is significantly decreased in the minor G allele construct compared with the major T construct in different cell types (47.2% reduction in LNCaP cells and 51.4% reduction in PC3 cells). (**B**) Quantitative real-time polymerase chain reaction (PCR) analysis of *MTR in vivo* mRNA expression in 52 human prostate tissue samples with different rs28372871 T \> G genotypes. All values have been normalized to the level of *GAPDH*. (**C**) In luciferase assays, a plasmid construct with the minor A allele manifested luciferase activity significantly reduced by 31.1% compared with the major G allele in LNCaP cells. This value was 26.0% in PC3 cells. (**D**) Quantitative real-time polymerase chain reaction analysis of *MTR in vivo* mRNA expression in 52 human prostate tissue samples with different rs1131450 G \> A genotypes. All values have been normalized to the level of *GAPDH*. Each value represents the mean ± SD of three independent experiments, and each experiment was performed in triplicate. \*\*\*indicates *P* \< 0.001.](srep36264-f1){#f1}

![The functional *MTR* variants rs28372871 T \> G and rs1131450 G \> A correlate with human plasma homocysteine concentrations.\
(**A**) Homocysteine concentrations were significantly different between the groups with different rs28372871 T \> G genotypes in the PCa cohort, the control cohort and the entire cohort. (**B**) Homocysteine concentrations were significantly different between the groups with different rs1131450 G \> A genotypes in the PCa cohort, the control cohort and the entire cohort. The data shown are expressed as the mean ± SD. \*indicates *P* \< 0.05, \*\*indicates *P* \< 0.01, \*\*\*indicates *P* \< 0.001.](srep36264-f2){#f2}

![Down-regulation of *MTR* contributes to elevated cellular homocysteine and SAH levels, reduced methionine and SAM levels, and increased SAH/SAM ratio in PC3 cells.\
(**A**) Knockdown efficiency of gradient *MTR* siRNA was measured using quantitative real-time polymerase chain reaction. (**B**) Cellular homocysteine concentration after transfection with gradient *MTR* siRNA. (**C**) Cellular methionine level after transfected with gradient MTR siRNA. (**D**) Cellular SAM level after transfection with gradient *MTR* siRNA. (**E**) Cellular SAH level after transfection with gradient *MTR* siRNA. (**F**) Ratio of SAH/SAM after transfection with gradient *MTR* siRNA. Each value represents the mean ± SD of three independent experiments, and each experiment was performed in triplicate.](srep36264-f3){#f3}

![Down-regulation of *MTR* significantly increased PCa cell invasion but did not alter cell proliferation *in vitro*.\
(**A**) The knockdown efficiency of *MTR* siRNA was measured using quantitative real-time polymerase chain reaction. (**B**) Down-regulation of *MTR* did not alter LNCaP cell proliferation. (**C**) Down-regulation of *MTR* did not alter PC3 cell proliferation. (**D**) Down-regulation of *MTR* significantly increased invasion by PC3 cells. Each value represents the mean ± SD of three independent experiments, and each experiment was performed in triplicate.](srep36264-f4){#f4}

###### Demographic and clinicopathological characteristics of 1817 PCa patients and 2026 controls included in the study.

  Variables                           Cases (n = 1817)   Controls (n = 2026)      *P*
  ---------------------------------- ------------------ --------------------- -----------
  Age (yr), mean ± SD                    66.7 ± 7.2          66.9 ± 6.8          0.437
  BMI (Kg/m2), n (%)                                                             0.877
   \<25                                 1308 (72.0)          1463 (72.2)            
   ≥25                                   509 (28.0)          563 (27.8)             
  Hypertension, n (%)                                                            0.424
   No                                   1054 (58.0)          1201 (59.3)            
   Yes                                   763 (42.0)          825 (40.7)             
  Diabetes mellitus, n (%)                                                       0.926
   No                                   1636 (90.0)          1826 (90.1)            
   Yes                                   181 (10.0)           200 (9.9)             
  Cardiovascular disease, n (%)                                                  0.631
   No                                   1660 (91.4)          1842 (90.9)            
   Yes                                   157 (8.6)            184 (9.1)             
  PSA (ng/mL), mean ± SD                 28.5 ± 1.3           1.2 ± 0.3         \< 0.001
  Gleason score, n (%)                                                              
   ≤6                                    289 (15.9)                                 
   7                                     923 (50.8)                                 
   ≥8                                    605 (33.3)                                 
  Pathological tumor stage, n (%)                                                   
   T2                                   1231 (67.7)                                 
   T3a                                   160 (8.8)                                  
   T3b                                   426 (23.4)                                 
  Positive surgical margins, n (%)       352 (19.4)                                 
  Lymph node involvement, n (%)          154 (8.5)                                  

###### Associations between genetic polymorphisms in homocysteine removal genes and PCa risk in Han Chinese men.

  Gene         SNP           Type             Genotype        Cases (n = 1817)   Controls (n = 2026)         *P*^HWE^            Crude OR (95% CI)              *P*            Adjusted OR (95% CI)^c^    *P*^a^
  -------- ------------ --------------- -------------------- ------------------ --------------------- ----------------------- ----------------------- ----------------------- ------------------------- -----------
  *MTR*     rs28372871     Promoter              TT              449 (24.7)          579 (28.6)                0.180                   1.00             **3 × 10**^**-4**^              1.00                  
                                                 TG              910 (50.1)          1037 (51.2)                                 1.13 (0.97--1.32)                                1.13 (0.96--1.33)           
                                                 GG              458 (25.2)          410 (20.2)                                **1.44 (1.20--1.73)**                            **1.40 (1.15--1.71)**    **0.004**
                                           Dominant model                                              **1.22 (1.06--1.73)**         **0.007**         **1.20 (1.03--1.41)**          **0.020**         
                                          Recessive model                                              **1.33 (1.14--1.55)**    **2 × 10**^**-4**^     **1.29 (1.10--1.53)**          **0.002**         
                                         Log-additive model                                            **1.20 (1.09--1.31)**    **1 × 10**^**-4**^     **1.18 (1.07--1.30)**          **0.001**         
            rs1131450       3\'UTR               GG             1045 (57.5)          1267 (62.5)               0.120                   1.00             **2 × 10**^**-4**^              1.00                  
                                                 GA              664 (36.5)          685 (33.8)                                **1.18 (1.03--1.34)**                              1.14 (0.98-1.32)            
                                                 AA              108 (5.9)            74 (3.7)                                 **1.77 (1.30--2.41)**                            **1.64 (1.17--2.31)**    **0.007**
                                           Dominant model                                              **1.23 (1.08--1.40)**         **0.001**         **1.19 (1.03--1.37)**          **0.017**         
                                          Recessive model                                              **1.67 (1.23--2.26)**    **8 × 10**^**-4**^     **1.57 (1.12--2.20)**          **0.009**         
                                         Log-additive model                                            **1.24 (1.11--1.38)**    **1 × 10**^**-4**^     **1.20 (1.06--1.35)**          **0.003**         
            rs1805087    Nonsynonymous           AA             1481 (81.5)          1692 (83.5)               0.960                   1.00                    0.182                    1.00                  
                          (Asp → Gly)            AG              316 (17.4)          319 (15.7)                                  1.13 (0.95--1.34)                                1.11 (0.92--1.34)           
                                                 GG               20 (1.1)            15 (0.7)                                   1.52 (0.78--2.99)                                1.72 (0.83--3.53)      **0.190**
                                           Dominant model                                                1.15 (0.97--1.36)             0.102             1.14 (0.95--1.37)            **0.160**         
                                          Recessive model                                                1.49 (0.76--2.92)             0.240             1.69 (0.82--3.47)            **0.150**         
                                         Log-additive model                                              1.15 (0.99--1.34)             0.074             1.15 (0.97--1.36)            **0.100**         
  *MTRR*     rs326119      Intron-1              AA              896 (49.3)          944 (46.6)                0.880                   1.00                    0.220                    1.00                  
                                                 AC              757 (41.7)          881 (43.5)                                  0.91 (0.79--1.03)                                0.91 (0.79--1.05)           
                                                 CC              164 (9.0)            201 (9.9)                                  0.86 (0.69--1.08)                                0.86 (0.67--1.10)        0.310
                                           Dominant model                                                0.90 (0.79--1.02)             0.092             0.90 (0.78--1.04)              0.140           
                                          Recessive model                                                0.90 (0.73--1.12)             0.345             0.90 (0.71--1.14)              0.390           
                                         Log-additive model                                              0.92 (0.83--1.01)             0.087             0.92 (0.83--1.03)              0.130           
            rs1801394    Nonsynonymous           AA              985 (54.2)          1111 (54.8)               0.420                   1.00                    0.831                    1.00               0.89
                          (Ile → Met)            AG              706 (38.9)          769 (38.0)                                  1.04 (0.91--1.18)                                0.99 (0.85--1.14)           
                                                 GG              126 (6.9)            146 (7.2)                                  0.97 (0.76--1.25)                                0.93 (0.71--1.24)           
                                           Dominant model                                                1.03 (0.90--1.16)             0.697             0.98 (0.85--1.13)              0.770           
                                          Recessive model                                                0.96 (0.75--1.23)             0.743             0.94 (0.71--1.23)              0.650           
                                         Log-additive model                                              1.01 (0.91--1.12)             0.860             0.98 (0.87--1.09)              0.670           
  *CBS*     rs2850144      Promoter              CC              774 (42.6)          844 (41.7)                0.180                   1.00                    0.818                    1.00               0.910
                                                 CG              803 (44.2)          905 (44.7)                                  0.97 (0.84--1.11)                                0.98 (0.84--1.14)           
                                                 GG              240 (13.2)          277 (13.7)                                  0.94 (0.77--1.15)                                0.96 (0.77--1.19)           
                                           Dominant model                                                0.96 (0.85--1.09)             0.556             0.97 (0.85--1.12)              0.710           
                                          Recessive model                                                0.96 (0.80--1.16)             0.674             0.97 (0.79--1.18)              0.740           
                                         Log-additive model                                              0.97 (0.89--1.06)             0.530             0.98 (0.88--1.08)              0.670           

OR, odds ratio; 95% CI, 95% confidence interval.

^HWE^*P* value for the Hardy-Weinberg equilibrium test in control subjects.

^a^Adjusted for age, BMI, hypertension, diabetes mellitus and cardiovascular disease in multivariant logistic regression models.

###### Stratified analysis for associations between genetic polymorphisms in homocysteine removal genes and PCa risk by recessive genetic model in Han Chinese men.

          Variables            rs28372871 (cases/controls)      Adjusted OR[a](#t2-fn1){ref-type="fn"} (95% CI)              *P*                     *P*^hom^              rs1131450 (cases/controls)       Adjusted OR[a](#t2-fn1){ref-type="fn"} (95% CI)       *P*           *P*^hom^            rs1805087 (cases/controls)       Adjusted OR[a](#t2-fn1){ref-type="fn"} (95% CI)        *P*       *P*^hom^                                        
  -------------------------- ------------------------------- ----------------------------------------------------- ----------------------- ---------------------------- -------------------------------- ----------------------------------------------------- --------- ----------------------- -------------------------------- ----------------------------------------------------- ----------- ------------ ------------------------ ----------- -------
       Age (yr), median                                                                                                                                                                                                                                                                                                                                                                                                                               
              ≤68                       762/1031                                    253/274                           1.21 (0.95--1.53)               0.120                          0.294                                     959/1260                          56/45    **1.77 (1.08--2.88)**             **0.022**                                     0.970                          1006/1293      9/12        0.81 (0.29--2.23)        0.680     0.115
             \>68                        597/585                                    205/136                         **1.42 (1.04--1.96)**           **0.028**                                                                   750/692                          52/29      1.53 (0.81--2.88)                 0.180                                                                       791/718       11/3        3.14 (0.73--13.49)       0.110        
         BMI (kg/m2)                                                                                                                                                                                                                                                                                                                                                                                                                                  
             ＜25                       993/1166                                    315/297                           1.22 (0.92--1.51)               0.074                          0.193                                     1233/1410                         75/53      1.49 (0.99--2.22)                 0.053                                       0.768                          1292/1452     16/11       1.79 (0.0.79--4.10)       0.160     0.631
              ≥25                        366/450                                    143/113                         **1.47 (1.07--2.01)**           **0.016**                                                                   476/542                          33/21      1.83 (0.97--3.45)                 0.061                                                                       505/559       4/4         1.30 (0.29--5.89)        0.730        
         Hypertension                                                                                                                                                                                                                                                                                                                                                                                                                                 
              No                         801/954                                    253/247                           1.14 (0.91--1.43)               0.250                          0.199                                     994/1160                          60/41      1.51 (0.95--2.42)                 0.081                                       0.851                          1045/1190      9/11        1.06 (0.39--2.87)        0.920     0.113
              Yes                        558/662                                    205/163                         **1.45 (1.11--1.90)**           **0.006**                                                                   715/792                          48/33      1.50 (0.88--2.57)                 0.140                                                                       752/821       11/4      **4.17 (1.10--15.83)**   **0.026**      
      Diabetes mellitus                                                                                                                                                                                                                                                                                                                                                                                                                               
              No                        1224/1463                                   412/363                         **1.35 (1.13--1.61)**   **9** **×** **10**^**−4**^               0.425                                     1539/1760                         97/66    **1.55 (1.08--2.21)**             **0.017**                                     0.875                          1620/1812     16/14        1.49 (0.69--3.23)        0.320     0.997
              Yes                        135/153                                     46/47                            0.86 (0.48--1.54)               0.620                                                                     170/192                          11/8       2.38 (0.82--6.87)                 0.110                                                                       177/199       4/1         4.20 (0.27--64.20)       0.290        
    Cardiovascular disease                                                                                                                                                                                                                                                                                                                                                                                                                            
              No                        1254/1467                                   406/375                           1.21 (0.92--1.46)               0.067                          0.055                                     1558/1779                        101/63    **1.80 (1.26--2.58)**             **0.001**                                     0.078                          1646/1827     14/15        1.10 (0.50--2.44)        0.810     0.061
              Yes                        105/149                                     52/35                          **2.32 (1.26--4.25)**           **0.006**                                                                   151/173                          7/11       0.37 (0.10--1.36)                 0.120                                                                       151/184       6/0          **NA (0.00-NA)**      **0.005**      
        Gleason score                                                                                                                                                                                                                                                                                                                                                                                                                                 
              ≤7                        932/1616                                    280/410                           1.13 (0.93--1.38)               0.220                        **0.017**                                   1153/1952                         59/74      1.10 (0.73--1.66)                 0.660                                     **0.037**                        1204/2011      8/15        1.05 (0.41--2.71)        0.910     0.057
              ≥8                        427/1616                                    178/410                         **1.67 (1.31--2.14)**          **\<0.0001**                                                                556/1952                          49/74    **2.83 (1.78--4.48)**            **\<0.0001**                                                                  593/2011      12/15      **2.79 (1.13--6.87)**    **0.028**      
   Extracapsular extension                                                                                                                                                                                                                                                                                                                                                                                                                            
              No                        961/1616                                    270/410                           1.03 (0.84--1.25)               0.780                       **\<0.0001**                                 1171/1952                         60/74      1.20 (0.81--1.79)                 0.370                                     **0.033**                        1218/2011     13/15        1.42 (0.64--3.17)        0.390     0.835
              Yes                       398/1616                                    188/410                         **2.08 (1.62--2.67)**          **\<0.0001**                                                                538/1952                          48/74    **2.41 (1.51--3.87)**     **3** **×** **10**^**−4**^                                                           579/2011       7/15        2.63 (0.86--8.05)        0.099        
   Seminal vesicle invasion                                                                                                                                                                                                                                                                                                                                                                                                                           
              No                        1074/1616                                   317/410                           1.11 (0.92--1.34)               0.260                       **\<0.0001**                                 1321/1952                         70/74      1.22 (0.83--1.79)                 0.310                                     **0.022**                        1375/2011     16/15        1.78 (0.83--3.82)        0.140     0.761
              Yes                       285/1616                                    141/410                         **2.12 (1.60--2.82)**          **\<0.001**                                                                 388/1952                          38/74    **3.08 (1.83--5.18)**            **\<0.0001**                                                                  422/2011       4/15        1.51 (0.39--5.89)        0.560        
   Positive surgical margin                                                                                                                                                                                                                                                                                                                                                                                                                           
              No                        1094/1616                                   371/410                         **1.29 (1.08--1.54)**           **0.006**                        0.837                                     1383/1952                         82/74    **1.51 (1.05--2.16)**             **0.026**                                     0.300                          1450/2011     15/15        1.43 (0.67--3.09)        0.360     0.601
              Yes                       265/1616                                    87/410                            1.29 (0.93--1.81)               0.140                                                                    326/1952                          26/74      1.79 (0.95--3.36)                 0.078                                                                      347/2011       5/15        3.09 (0.81--11.71)       0.110        
    Lymph node involvement                                                                                                                                                                                                                                                                                                                                                                                                                            
              No                        1259/1616                                   404/410                         **1.23 (1.04--1.47)**           **0.017**                      **0.007**                                   1569/1952                         94/74    **1.45 (1.02--2.05)**             **0.039**                                     0.133                          1644/2011     19/15        1.75 (0.85--3.64)        0.130     0.198
              Yes                       100/1616                                    54/410                          **1.96 (1.27--3.02)**           **0.003**                                                                  140/1952                          14/74    **3.02 (1.39--6.57)**             **0.008**                                                                    153/2011       1/15        1.93 (0.18--21.10)       0.610        
        **Variables**         **rs326119 (cases/controls)**   **Adjusted OR[a](#t2-fn1){ref-type="fn"} (95% CI)**          ***P***                  ***Phom***           **rs1801394 (cases/controls)**   **Adjusted OR[a](#t2-fn1){ref-type="fn"} (95% CI)**   ***P***        ***Phom***         **rs2850144 (cases/controls)**   **Adjusted OR[a](#t2-fn1){ref-type="fn"} (95% CI)**    ***P***    ***Phom***                                       
          **AA/AC**                      **CC**                                    **AA/AG**                               **GG**                   **CC/CG**                        **GG**                                                                                                                                                                                                                                                           
       Age (yr), median                                                                                                                                                                                                                                                                                                                                                                                                                               
              ≤68                       925/1181                                    90/124                            0.93 (0.70--1.23)               0.600                          0.701                                     938/1205                         77/100      0.99 (0.73--1.35)                 0.940                                       0.894                          888/1140     127/165       0.99 (0.77--1.27)        0.920     0.593
             \>68                        728/644                                     74/77                            0.82 (0.53--1.26)               0.360                                                                     753/675                          49/46      1.07 (0.63--1.80)                 0.810                                                                       689/609     113/112       0.91 (0.64--1.30)        0.610        
         BMI (kg/m2)                                                                                                                                                                                                                                                                                                                                                                                                                                  
             ＜25                       1190/1319                                   118/144                           0.89 (0.68--1.18)               0.430                          0.905                                     1215/1365                         93/98      1.07 (0.78--1.48)                 0.660                                       0.197                          1146/1275    162/188       0.92 (0.72--1.18)        0.530     0.979
              ≥25                        463/506                                     46/57                            0.91 (0.57--1.43)               0.670                                                                     476/515                          33/48      0.70 (0.42--1.16)                 0.160                                                                       431/474      78/89        1.07 (0.74--1.54)        0.710        
         Hypertension                                                                                                                                                                                                                                                                                                                                                                                                                                 
              No                        959/1067                                    95/134                            0.77 (0.56--1.05)               0.096                          0.195                                     977/1122                          77/79      1.17 (0.81--1.68)                 0.400                                       0.153                          907/1033     147/168       0.96 (0.73--1.26)        0.780     0.647
              Yes                        694/758                                     67/69                            1.30 (0.88--1.94)               0.190                                                                     714/758                          49/67      0.74 (0.47--1.18)                 0.200                                                                       670/716      93/109       0.95 (0.67--1.35)        0.790        
      Diabetes mellitus                                                                                                                                                                                                                                                                                                                                                                                                                               
              No                        1481/1641                                   155/185                           0.92 (0.72--1.18)               0.530                          0.330                                     1519/1695                        117/131     0.98 (0.74--1.31)                 0.910                                       0.339                          1421/1573    215/253       0.93 (0.75--1.16)        0.530     0.489
              Yes                        172/184                                     9/16                             0.33 (0.10--1.15)               0.064                                                                     172/185                          9/15       0.59 (0.20--1.74)                 0.330                                                                       156/176      25/24        1.66 (0.81--3.38)        0.170        
    Cardiovascular disease                                                                                                                                                                                                                                                                                                                                                                                                                            
              No                        1512/1654                                   148/188                           0.85 (0.66--1.09)               0.200                          0.177                                     1543/1712                        117/130     0.99 (0.74--1.32)                 0.950                                       0.322                          1441/1595    219/247       1.00 (0.80--1.24)        0.990     0.509
              Yes                        141/171                                     16/13                            1.91 (0.73--4.99)               0.190                                                                     148/168                          9/16       0.52 (0.17--1.54)                 0.220                                                                       136/154      21/30        1.18 (0.55--2.50)        0.670        
        Gleason score                                                                                                                                                                                                                                                                                                                                                                                                                                 
              ≤7                        1104/1825                                   108/201                           0.97 (0.74--1.29)               0.850                          0.836                                     1126/1880                        86/146      0.99 (0.72--1.36)                 0.970                                       0.744                          1058/1749    154/277       0.90 (0.71--1.14)        0.390     0.449
              ≥8                        549/1825                                    56/201                            0.80 (0.55--1.16)               0.230                                                                    565/1880                         40/146      0.87 (0.57--1.34)                 0.530                                                                      519/1749      86/277       1.09 (0.80--1.49)        0.570        
   Extracapsular extension                                                                                                                                                                                                                                                                                                                                                                                                                            
              No                        1129/1825                                   102/201                           0.83 (0.63--1.10)               0.190                          0.176                                     1146/1880                        85/146      0.91 (0.67--1.25)                 0.570                                       0.951                          1069/1749    162/277       0.95 (0.75--1.21)        0.680     0.940
              Yes                       524/1825                                    62/201                            1.11 (0.78--1.59)               0.560                                                                    545/1880                         41/146      1.01 (0.66--1.55)                 0.970                                                                      508/1749      78/277       0.96 (0.70--1.32)        0.810        
   Seminal vesicle invasion                                                                                                                                                                                                                                                                                                                                                                                                                           
              No                        1271/1825                                   120/201                           0.89 (0.68--1.16)               0.370                          0.351                                     1297/1880                        94/146      0.92 (0.68--1.24)                 0.590                                       0.642                          1208/1749    183/277       0.95 (0.76--1.19)        0.650     0.917
              Yes                       382/1825                                    44/201                            1.00 (0.66--1.52)               1.000                                                                    394/1880                         32/146      1.05 (0.65--1.72)                 0.830                                                                      369/1749      57/277       0.99 (0.69--1.42)        0.940        
   Positive surgical margin                                                                                                                                                                                                                                                                                                                                                                                                                           
              No                        1339/1825                                   126/201                           0.84 (0.65--1.09)               0.200                          0.257                                     1366/1880                        99/146      0.89 (0.66--1.19)                 0.410                                       0.594                          1266/1749    199/277       0.98 (0.79--1.21)        0.830     0.389
              Yes                       314/1825                                    38/201                            1.13 (0.71--1.79)               0.600                                                                    325/1880                         27/146      1.28 (0.72--2.26)                 0.410                                                                      311/1749      41/277       0.89 (0.58--1.36)        0.580        
    Lymph node involvement                                                                                                                                                                                                                                                                                                                                                                                                                            
              No                        1519/1825                                   144/201                           0.86 (0.67--1.11)               0.240                          0.100                                     1551/1880                        112/146     0.91 (0.68--1.20)                 0.500                                       0.310                          1443/1749    220/277       0.98 (0.80--1.21)        0.870     0.936
              Yes                       134/1825                                    20/201                            1.23 (0.66--2.26)               0.520                                                                    140/1880                         14/146      1.51 (0.75--3.06)                 0.260                                                                      134/1749      20/277       0.97 (0.54--1.74)        0.930        

OR, odds ratio; 95% CI, 95% confidence interval.

^hom^*P* value for homogeneity test using the χ^2^-based Q-test.

^a^Adjusted for age, BMI, hypertension, diabetes mellitus, and cardiovascular disease in multivariant logistic regression models.
